Minireviews
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2019; 7(13): 1571-1581
Published online Jul 6, 2019. doi: 10.12998/wjcc.v7.i13.1571
Cholestatic liver diseases: An era of emerging therapies
Hrishikesh Samant, Wuttiporn Manatsathit, David Dies, Hosein Shokouh-Amiri, Gazi Zibari, Moheb Boktor, Jonathan Steve Alexander
Hrishikesh Samant, Moheb Boktor, Division of Gastroenterology and Hepatology, Department of medicine, LSU health, Shreveport, LA 71103, United States
Hrishikesh Samant, David Dies, Hosein Shokouh-Amiri, Gazi Zibari, John C McDonald Transplant Center, Willis Knighton Medical Center, Shreveport, LA 71103, United States
Wuttiporn Manatsathit, Division of Gastroenterology and Hepatology, University of Nebraska, Omaha, NE 68194, United States
Jonathan Steve Alexander, Department of Molecular and Cellular Physiology, Louisiana State University, School of Medicine, Shreveport, LA 71103, United States
Author contributions: Samant H did literature search and wrote the paper. Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G and Boktor M gave inputs and reviewed it. Alexander JS did critical edit, figures construction and finalize the article.
Conflict-of-interest statement: The authors declare that there is no conflict of interest regarding the publication of this paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jonathan Steve Alexander, FACG, PhD, Professor, Department of Molecular and Cellular Physiology, Louisiana State University, School of Medicine, 1501 Kings Highway, Shreveport, LA 71103, United States. jalexa@lsuhsc.edu
Telephone: +1-318-6754151 Fax: +1-318-6754156
Received: January 10, 2019
Peer-review started: January 10, 2019
First decision: January 30, 2019
Revised: June 5, 2019
Accepted: June 10, 2019
Article in press: June 10, 2019
Published online: July 6, 2019
Processing time: 177 Days and 15.8 Hours
Core Tip

Core tip: Anti-cholestatic therapeutic options now go beyond ursodeoxycholic acid (UDCA) and target nuclear receptors regulating bile acid (farnesoid X receptor) and G protein-coupled receptor and fibroblast growth factor-19. Additionally, enterohepatic bile acid transporters and norUDCA represent potential targets in cholestatic disease.